# ULBI earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ULBI) · [Earnings tab](https://www.lopjlb.com/stock/ULBI?tab=earnings)

Updated: 2026-07-27T01:43:05

Quarters analyzed: 8

## Cross-quarter narrative

Across eight earnings calls from Q2 2024 to Q1 2026 Ultralife’s story shifted from a record‑high battery gross margin and aggressive debt reduction to a cycle of margin volatility, integration milestones, and persistent external headwinds. Early calls highlighted a 26.9% battery gross margin and a growing $93 M backlog, but by Q4 2024 margin pressure emerged as gross margin slipped to 24.2% amid lower medical battery sales and acquisition costs. The Electrochem acquisition became a central narrative; integration was repeatedly described as on‑track, later delivered, and tied to ERP carve‑out delays and accounting close issues. Backlog expanded steadily to $115 M by Q1 2026, reflecting strong defense demand and diversified orders, yet tariff‑related cash‑flow pressure and supply‑chain disruptions repeatedly eroded gross margins, which fell to 21.3% in Q1 2026. Government contract timing and potential military spending cuts surfaced as new concerns, while earlier regulatory and legal risks faded from discussion. Product rollout momentum accelerated with multiple new amplifiers, thin‑cell batteries, and power systems moving toward production, though some items remained at risk. Overall the company moved from growth optimism to a more cautious stance, balancing integration success against lingering cost and demand uncertainties.

## Latest CallCard · Q1

Ultralife Q1 2026 revenue $47.4M with operating loss $0.2M; record backlog $115.1M but gross margin fell 380 bps to 21.3% due to production disruptions; new product launches and vertical integration initiatives underway. No Q&A session. Management tone cautiously optimistic but defensive on near-ter

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** Ultralife Q1 2026 revenue $47.4M with operating loss $0.2M; record backlog $115.1M but gross margin fell 380 bps to 21.3% due to production disruptions; new product launches and vertical integration initiatives underway. No Q&A session. Management tone cautiously optimistic but defensive on near-ter
- **2025 Q4:** Ultralife posted Q4 2025 revenue up 10.6% to $48.5M but a $10.6M operating loss, highlighted a $110M backlog, ongoing Electrochem integration and new product rollouts while noting margin gains and order delays.
- **2025 Q3:** —
- **2025 Q2:** ULBI Q2 sales $48.6M, margins pressured by tariffs, mix, Comm Systems delays; Electrochem integration on track; multiple new products in qualification targeting 2026 revenue.','tone': {'mgmt': 0.1, 'mgmt_rationale': 'CEO acknowledges Q2 headwinds (tariffs, mix, order timing) but expresses optimism f
- **2025 Q1:** Ultralife Q1 2025 revenue rose 21% to $50.7M, operating income fell, Electrochem integration on track, tariff impacts pressuring cash flow, margin down but initiatives underway, backlog healthy and demand visible.
- **2024 Q4:** Ultralife posted Q4 2024 sales of $43.9M, highlighted Electrochem integration progress, noted margin pressure and delayed shipments, but expressed optimism for a strong 2025 despite integration and demand uncertainties.
- **2024 Q3:** ULBI Q3 sales $35.7M, EPS $0.02; Battery up 1.9%, Comm Systems down 58%; Electrochem acquisition closed Oct 31; backlog $78M; margin pressure from mix and delays; material deflation and lean initiatives progressing.','tone':{'mgmt':0.1,'mgmt_rationale':'Management highlights progress on three key in
- **2024 Q2:** ULBI Q2: $43M sales, $3.9M operating income, 3rd straight quarter $42M+ sales; Battery segment record revenue, gross margin 26.9% (+210bps YoY), debt cut 52%, backlog $93M; Communications Systems down 28.7%; Thin Cell, Thionyl, conformal battery updates; new sales hires; Russell 2000 inclusion.','to

## Theme arcs

- **Gross margin trajectory** (deteriorating): Margins fell from 26.9% (Q2 2024) to 21.3% (Q1 2026) after a brief rebound in Q4 2025.
- **Electrochem integration** (improving): Progressed from on‑track (Q4 2024) to delivered (Q4 2025).
- **Backlog growth** (improving): Backlog grew from $93 M (Q2 2024) to $115 M (Q1 2026).
- **Tariff impact on cash flow** (deteriorating): Tariff pressures first noted Q1 2025 and persisted through Q2 2025.
- **Supply‑chain disruptions** (stable): Repeated delays in Communications Systems shipments across multiple quarters.
- **Government contract timing** (new): First highlighted Q1 2025 and re‑emerged Q4 2025.
- **Military spending risk** (new): Raised as a potential headwind in Q4 2025.
- **Product adoption uncertainty** (new): Uncertainty around new product acceptance noted Q4 2025.

## Fear persistence

- **Supply‑chain disruptions** [recurring]: Repeated delays in Communications Systems shipments across Q4 2024, Q1 2025, Q4 2025, Q1 2026.
- **Tariff impacts** [recurring]: First noted Q1 2025 and persisted through Q2 2025.
- **Integration risk** [recurring]: Ongoing ERP and accounting close challenges mentioned Q4 2024, Q1 2025, resolved by Q4 2025.
- **Macro demand weakness** [recurring]: Cited Q4 2024 and again as economic uncertainty Q4 2025.
- **Regulatory risk** [resolved]: Medical wearable regulatory concerns raised Q4 2024 but not mentioned later.
- **Legal/insurance claim** [resolved]: Business interruption claim issue noted Q4 2024 only.
- **Government contract timing** [recurring]: Highlighted Q1 2025 and re‑emerged Q4 2025.

## Guidance path

2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:maintained → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/ULBI`